Table of Contents
I. NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed) RFA-AT-21-003
II. Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) NIDA Funding Opportunities PAR-20-225 for Early Stage Investigators
III. Other NIDA Funding Opportunities https://www.drugabuse.gov/funding/nida-funding-opportunities
I. NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed) RFA-AT-21-003;
Letter of Intent Due Date: November 18, 2020
Application Due Date: December 18, 2020 by 5:00 PM local time of applicant organization.
he NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/).
The goal of this FOA is to enhance our fundamental understanding of interoception with a specific focus on dissecting and determining the function of neural circuits that connects peripheral organs/tissues with the central nervous system (CNS) via peripheral ganglia. For this FOA, interoception science includes studies of the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself. This FOA encourages projects that combine diverse expertise and use innovative approaches to delineate interoceptive mechanisms at the molecular, cellular, circuitry, functional, and/or behavioral levels. Outcomes of this research will lay a critical foundation for future translational and clinical research on interoception as well as its roles in nervous system disorders. Studies of interoceptive neural circuits exclusively within the CNS may be more appropriate for The BRAIN Initiative funding opportunities. Applications in response to this FOA should budget for an annual investigator meeting organized by the NIH Blueprint for Neuroscience Research. Human subject research is not allowed for this FOA. (For more details and instructions please read the entire funding opportunity Announcement).
II. Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) NIDA Funding Opportunities PAR-20-225 for Early Stage Investigators
Application due date: October 19, 2020 by 5:00 PM local time of applicant organization.
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders. Frequently Asked Questions (FAQ). (For more details and instructions please read the entire funding opportunity Announcement).
III. Other NIDA Funding Opportunities
- Notices
- Notices of Special Interest
- Active NIDA Requests for Applications (RFAs)
- Active NIDA Program Announcements (PAs)
-----------
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-
No comments:
Post a Comment